J Korean Med Sci.  2009 Jan;24(Suppl 1):S38-S43. 10.3346/jkms.2009.24.S1.S38.

Association of Angiotensin II Type 2 Receptor Gene A1818T Polymorphism with Progression of Immunoglobulin A Nephropathy in Korean Patients

• Yoon HJ
• Chin HJ
• Na KY
• Chae DW
• Kim S
• Jeon US
• Chung WK
• Lee HH
• Yang J
• Kim S
• Kwon YJ
• Kim HC
• Park SB
• Kim HY
• Lee TW
• The Progressive REnal disease and Medical Informatics and gEnomics Research (PREMIER) members

• KMID: 1778138
• DOI: http://doi.org/10.3346/jkms.2009.24.S1.S38

Abstract

We determined the relationship between the progression of immunoglobulin A nephropathy (IgAN) and the A1818T polymorphism in intron 2 of Angiotensin II type 2 receptor (AT2R) gene, which might play protective roles in the pathogenesis of IgAN. Patients with biopsy-proven IgAN were recruited from the registry of the Progressive REnal disease and Medical Informatics and gEnomics Research (PREMIER) which was sponsored by the Korean Society of Nephrology. A1818T polymorphism of AT2R gene was analyzed with PCR-RFLP method and the association with the progression of IgAN, which was defined as over 50% increase in baseline serum creatinine level, was analyzed with survival analysis. Among the 480 patients followed for more than 10 months, the group without T allele had significantly higher rates of progression of IgAN than the group with T allele (11.4% vs. 3.9%, p=0.024), although there were no significant differences in the baseline variables such as initial serum creatinine level, the degree of proteinuria, and blood pressure. In the Cox's proportional hazard model, the hazard ratio of disease progression in the patients with T allele was 0.221 (95% confidence interval for Exp(B): 0.052-0.940, p=0.041) compared to that of without T allele. In conclusion, A1818T polymorphism of AT2R gene was associated with the progression of IgAN.

Keyword

Polymorphism, Single Nucleotide; Glomerulonephritis, IGA; Receptor, Angiotensin, Type 2

MeSH Terms

Alleles
Creatinine/blood
Disease Progression
Genotype
Glomerulonephritis, IGA/ethnology/*genetics
Humans
Korea
Models, Genetic
Models, Statistical
*Polymorphism, Genetic
Polymorphism, Restriction Fragment Length
*Polymorphism, Single Nucleotide
Receptor, Angiotensin, Type 2/*genetics
Time Factors
Treatment Outcome

Figure

• 

  Fig. 1 Kaplan-Meier curve of survivorship of immunoglobulin A nephropathy according to allelic difference.

Reference

1. Yagame M, Suzuki D, Jinde K, Saotome N, Murakami R, Asakura K, Nakashima R, Kashem A, Yano N, Endoh M, Nomoto Y, Sakai H, Tomino Y. Value of pathological grading in prediction of renal survival in IgA nephropathy. Nephrology. 1996. 2:107–117.

2. Koyama A, Igarashi M, Kobayashi M. Natural history and risk factors for immunoglobulin A nephropathy in Japan. Am J Kidney Dis. 1997. 29:526–532.

3. Li PK, Ho KK, Szeto CC, Yu L, Lai FM. Prognostic indicators of IgA nephropathy in the Chinese-clinical and pathological perspectives. Nephrol Dial Transplant. 2002. 17:64–69.

4. Frimat L, Briançon S, Hestin D, Aymard B, Renoult E, Huu TC, Kessler M. IgA nephropathy: prognostic classification of end-stage renal failure. Nephrol Dial Transplant. 1997. 12:2569–2575.

5. Rychlik I, Andrassy K, Waldherr R, Zuna I, Tesar V, Jancová E, Ste jskalová A, Ritz E. Clinical features and natural history of IgA nephropathy. Ann Med Interne. 1999. 150:117–126.

6. Vleming LJ, de Fijter JW, Westendorp RG, Daha MR, Bruijn JA, van Es LA. Histomorphometric correlates of renal failure in IgA nephropathy. Clinical Nephrol. 1998. 49:337–344.

7. D'Amico G, Colasanti G, Barbiano di Belgioioso G, Fellin G, Ragni A, Egidi F, Radaelli L, Fogazzi G, Ponticelli C, Minetti L. Long-term follow-up of IgA mesangial nephropathy: clinico-histological study in 374 patients. Semin Nephrol. 1987. 4:355–358.

8. Hsu SI, Ramirez SB, Winn MP, Bonventre JV, Owen WF. Evidence for genetic factors in the development and progression of IgA nephropathy. Kidney Int. 2000. 57:1818–1835.

9. Frimat L, Kessler M. Controversies concerning the importance of genetic polymorphism in IgA nephropathy. Nephrol Dial Transplant. 2002. 17:542–545.

10. Suzuki S, Suzuki Y, Kobayashi Y, Harada T, Kawamura T, Yoshida H, Tomino Y. Insertion/deletion polymorphism in ACE gene is not associated with renal progression in Japanese patients with IgA nephropathy. Am J Kidney Dis. 2000. 35:896–903.

11. Goto S, Narita I, Saito N, Watanabe Y, Yamazaki H, Sakatsume M, Shimada H, Nishi S, Ueno M, Akazawa K, Arakawa M, Gejyo F. A(-20)C polymorphism of the angiotensinogen gene and progression of IgA nephropathy. Kidney Int. 2002. 62:980–985.

12. Carey RM. Update on the role of the AT₂ receptor. Curr Opin Nephrol Hypertens. 2005. 14:67–71.

13. Chan LY, Leung JC, Tang SC, Choy CB, Lai KN. Tubular Expression of Angiotensin II Receptors and Their Regulation in IgA Nephropathy. J Am Soc Nephrol. 2005. 16:2306–2317.

14. Pettersson-Fernholm K, Fröjdö S, Fagerudd J, Thomas MC, Forsblom C, Wessman M, Groop PH. FinnDiane Study Group. The AT2 gene may have a gender-specific effect on kidney function and pulse pressure in type 1 diabetic patients. Kidney Int. 2006. 69:1880–1884.

15. Levey AS, Greene T, Kusek JW, Beck GJ, Group MS. A simplified equation to predict glomerular filtration rate from serum creatinine [Abstract]. J Am Soc Nephrol. 2000. 11:A0828.

16. Hiraoka M, Taniguchi T, Nakai H, Kino M, Okada Y, Tanizawa A, Tsukahara H, Ohshima Y, Muramatsu I, Mayumi M. No evidence for AT2R gene derangement in human urinary tract abnormalies. Kidney Int. 2001. 59:1244–1249.

17. Barratt J, Feehally J, Smith AC. Pathogenesis of IgA nephropathy. Semin Nephrol. 2004. 24:197–217.

18. Nishimura H, Yerkes E, Hohenfellner K, Miyazaki Y, Ma J, Hunley TE, Yoshida H, Ichiki T, Threadgill D, Phillips JA 3rd, Hogan BM, Fogo A, Brock JW 3rd, Inagami T, Ichikawa I. Role of the angiotensin type 2 receptor gene in congenital anomalies of the kidney and urinary tract, CAKUT, of mice and men. Mol Cell. 1999. 3:1–10.

19. Falcón BL, Stewart JM, Bourassa E, Katovich MJ, Walter G, Speth RC, Sumners C, Raizada MK. Angiotensin II type 2 receptor gene transfer elicits cardioprotective effects in an angiotensin II infusion rat model of hypertension. Physiol Genomics. 2004. 19:255–261.

20. Kotani K, Sakane N, Saiga K, Tsuzaki K, Sano Y, Mu H, Kurozawa Y. The angiotensin II type 2 receptor gene polymorphism and body mass index in healthy Japanese women. Ann Clin Biochem. 2007. 44:83–85.

21. Jones A, Dhamrait SS, Payne JR, Hawe E, Li P, Toor IS, Luong L, Wootton PT, Miller GJ, Humphries SE, Montgomery HE. Genetic variants of angiotensin II receptors and cardiovascular risk in hypertension. Hypertension. 2003. 42:500–506.

22. Jin JJ, Nakura J, Wu Z, Yamamoto M, Abe M, Chen Y, Tabara Y, Yamamoto Y, Igase M, Bo X, Kohara K, Miki T. Association of angiotensin II type 2 receptor gene variant with hypertension. Hypertens Res. 2003. 26:547–552.

23. Miyaki K, Hara A, Araki J, Zhang L, Song Y, Kimura T, Omae K, Muramatsu M. C3123A polymorphism of the angiotensin II type 2 receptor gene and salt sensitivity in healthy Japanese men. J Hum Hypertens. 2006. 20:467–469.

24. Schmieder RE, Erdmann J, Delles C, Jacobi J, Fleck E, Hilgers K, Regitz-Zagrosek V. Effect of the angiotensin II type 2-receptor gene (+1675 G/A) on left ventricular structure in humans. J Am Coll Cardiol. 2001. 37:175–182.